P

Inventor

KHAN M AMIN

US61 patents
⚠️ This page may combine multiple inventors who share the name “KHAN M AMIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

APTINYX INC

24 patents
US9512134B2Dec 6, 2016

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC35 citations98
US10196401B2Feb 5, 2019

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC18 citations94
US10195179B2Feb 5, 2019

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC18 citations94
US10150769B2Dec 11, 2018

Spiro-lactam NMDA modulators and methods of using same

APTINYX INC20 citations94
US10052308B2Aug 21, 2018

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC19 citations94
US9932347B2Apr 3, 2018

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC19 citations94
US9925169B2Mar 27, 2018

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC19 citations94
US9828384B2Nov 28, 2017

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC24 citations94
US9758525B2Sep 12, 2017

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC23 citations94
US9738650B2Aug 22, 2017

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC22 citations94
US10441571B2Oct 15, 2019

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC12 citations93
US10441572B2Oct 15, 2019

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC11 citations93
US11028095B2Jun 8, 2021

Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC10 citations86
US10961189B2Mar 30, 2021

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC10 citations86
US10918637B2Feb 16, 2021

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC10 citations86
US11077094B2Aug 3, 2021

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC7 citations84
US10273239B2Apr 30, 2019

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC10 citations84
US10253032B2Apr 9, 2019

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC10 citations84
US11530223B2Dec 20, 2022

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC0 citations63
US11512051B2Nov 29, 2022

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC0 citations63
US11427585B2Aug 30, 2022

Spiro-lactam NMDA modulators and methods of using same

APTINYX INC0 citations63
US11376250B2Jul 5, 2022

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC1 citations63
US11370790B2Jun 28, 2022

Spiro-lactam NMDA modulators and methods of using same

APTINYX INC0 citations63
US11299495B2Apr 12, 2022

Spiro-lactam NMDA receptor modulators and uses thereof

APTINYX INC0 citations63

ALKERMES INC

14 patents
US5912015AJun 15, 1999

Modulated release from biocompatible polymers

ALKERMES INC557 citations99
US5656297AAug 12, 1997

Modulated release from biocompatible polymers

ALKERMES INC404 citations99
US5413797AMay 9, 1995

Controlled release ACTH containing microspheres

ALKERMES INC330 citations99
US6749866B2Jun 15, 2004

Modulated release from biocompatible polymers

ALKERMES INC76 citations98
US5667808ASep 16, 1997

Composition for sustained release of human growth hormone

ALKERMES INC194 citations98
US5654010AAug 5, 1997

Composition for sustained release of human growth hormone

ALKERMES INC353 citations98
US6368630B1Apr 9, 2002

Modulated release from biocompatible polymers

ALKERMES INC61 citations96
US6165508ADec 26, 2000

Controlled release of metal cation-stabilized interferon

ALKERMES INC39 citations96
US5711968AJan 27, 1998

Composition and method for the controlled release of metal cation-stabilized interferon

ALKERMES INC73 citations96
US6500448B1Dec 31, 2002

Composition for sustained release of human growth hormone

ALKERMES INC51 citations95
US6051259AApr 18, 2000

Composition for sustained release of human growth hormone

ALKERMES INC76 citations95
US5891478AApr 6, 1999

Composition for sustained release of human growth hormone

ALKERMES INC63 citations95
US6379701B1Apr 30, 2002

Controlled release of metal cation-stabilized interferon

ALKERMES INC21 citations93
US6780434B2Aug 24, 2004

Controlled release of metal cation-stabilized interferon

ALKERMES INC1 citations63

UNIV NORTHWESTERN

3 patents
US9512133B2Dec 6, 2016

NMDA receptor modulators and uses thereof

UNIV NORTHWESTERN27 citations94
US9802946B2Oct 31, 2017

NMDA receptor modulators and uses thereof

UNIV NORTHWESTERN22 citations93
US10906913B2Feb 2, 2021

NMDA receptor modulators and uses thereof

UNIV NORTHWESTERN10 citations85

TENACIA BIOTECHNOLOGY HONG KONG CO LTD

3 patents
US12167998B2Dec 17, 2024

Spiro-lactam NMDA receptor modulators and uses thereof

TENACIA BIOTECHNOLOGY HONG KONG CO LTD0 citations61
US12157736B2Dec 3, 2024

Spiro-lactam NMDA modulators and methods of using same

TENACIA BIOTECHNOLOGY HONG KONG CO LTD0 citations61
US12084444B2Sep 10, 2024

Spiro-lactam NMDA modulators and methods of using same

TENACIA BIOTECHNOLOGY HONG KONG CO LTD0 citations61

Aptinyx Incorporated

2 patents
US9579304B2Feb 28, 2017

Spiro-lactam NMDA receptor modulators and uses thereof

Aptinyx Incorporated26 citations97
US9504670B2Nov 29, 2016

Spiro-lactam NMDA receptor modulators and uses thereof

Aptinyx Incorporated28 citations97

NAUREX INC

1 patent
US9708335B2Jul 18, 2017

Spiro-lactam NMDA receptor modulators and uses thereof

NAUREX INC22 citations93

MOSKAL JOSEPH

1 patent
US8673843B2Mar 18, 2014

NMDA receptors modulators and uses thereof

MOSKAL JOSEPH32 citations93

ALKERMAS CONTROLLED THERAPEUTI

1 patent
US6514533B1Feb 4, 2003

Device for the sustained release of aggregation-stabilized, biologically active agent

ALKERMAS CONTROLLED THERAPEUTI15 citations82

APYTINYX INC

1 patent
US10316041B2Jun 11, 2019

Spiro-lactam NMDA receptor modulators and uses thereof

APYTINYX INC10 citations80

Showing the top 50 of 61 patents by PatentIndex Score.